Good riddance

Investors aren’t lamenting the end of 2016, but they are pinned between anxiety and optimism for the year ahead.

The anxiety stems from uncertainty about U.S. government policies for healthcare under the new administration. The continued issuance of sound bites by President-elect Donald Trump practically ensures that drug pricing will remain a significant overhang for the sector, at least until a policy stance is announced...